|
|
Article: Clinic Roundup.
- Article from:
- BIOWORLD Today
- Article date:
- September 16, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Acorda Therapeutics Inc., of Hawthorne, N.Y., said data from two long-term open-label extension studies of its multiple sclerosis investigational candidate Amaya (fampridine-SR) showed that 86 percent of participants remained on therapy after a maximum treatment time of 15 months in study MS-F204EXT, and 69.5 percent remained on therapy after a maximum treatment time of 36 months in study MS-F203EXT. The average treatment time for all patients was 10 months in the MS-F204EXT study and 26 months in the MS-F203EXT study, both inclusive of dropouts. The extension studies followed double-blind, placebo-controlled Phase III studies of fampridine-SR, MS-F203 and MS-F204 to ...